Literature DB >> 3232990

Screening for cystic fibrosis: a four year regional experience.

G Roberts1, M Stanfield, A Black, A Redmond.   

Abstract

A four year regional screening programme to detect cystic fibrosis using measurement of immunoreactive trypsinogen is described. During this period 60 infants were diagnosed; 34 by screening, 12 born with meconium ileus, and 14 not identified by the screening assay but who presented with clinical symptoms at a later age, giving an incidence of cyst fibrosis in the region during this time of 1/1807. Screening has resulted in earlier detection of cystic fibrosis in many infants, thus allowing treatment to be instituted at an early age, and genetic counseling offered to the parents. There were a number of false positives and false negatives with the immunoreactive trypsinogen screening assay. In addition, eight infants who were sweat tested at an early age had a sweat sodium concentration of less than 70 mmol/l, although they were subsequently shown to have cystic fibrosis. These results confirm other published data showing that sweat sodium results may be low in very young infants with cystic fibrosis. At the time of diagnosis seven (20%) of the infants identified by screening were totally asymptomatic and several additional children had symptoms of such a type that the diagnosis of cystic fibrosis had not been considered at the time of screening. Despite the problems experienced it has been decided to continue screening.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3232990      PMCID: PMC1779181          DOI: 10.1136/adc.63.12.1438

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Dried-blood spot screening for cystic fibrosis in the newborn.

Authors:  J R Crossley; R B Elliott; P A Smith
Journal:  Lancet       Date:  1979-03-03       Impact factor: 79.321

3.  A study of sweat sodium and chloride; criteria for the diagnosis of cystic fibrosis.

Authors:  A Green; P Dodds; C Pennock
Journal:  Ann Clin Biochem       Date:  1985-03       Impact factor: 2.057

4.  Screening for cystic fibrosis by died blood spot trypsin assay.

Authors:  A F Heeley; M E Heeley; D N King; J A Kuzemko; M P Walsh
Journal:  Arch Dis Child       Date:  1982-01       Impact factor: 3.791

5.  The sweat test: sodium and chloride values.

Authors:  H Shwachman; A Mahmoodian; R K Neff
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

6.  Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots.

Authors:  J R Crossley; P A Smith; B W Edgar; P D Gluckman; R B Elliott
Journal:  Clin Chim Acta       Date:  1981-06-18       Impact factor: 3.786

7.  Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants.

Authors:  B Wilcken; A R Brown; R Urwin; D A Brown
Journal:  J Pediatr       Date:  1983-03       Impact factor: 4.406

8.  Serological diagnosis of primary Sjögren's syndrome by means of human recombinant La (SS-B) as nuclear antigen.

Authors:  S Whittingham; G Naselli; L J McNeilage; R L Coppel; A D Sturgess
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

  8 in total
  8 in total

Review 1.  Neonatal screening--should we or shouldn't we?

Authors:  P H Weller; J V West
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

2.  False positive results with immunoreactive trypsinogen screening for cystic fibrosis owing to trisomy 13.

Authors:  F J Priest; N C Nevin
Journal:  J Med Genet       Date:  1991-08       Impact factor: 6.318

3.  Delayed diagnosis of cystic fibrosis due to normal sweat electrolytes.

Authors:  I M Doughty; I Ward; M Schwarz; T J David
Journal:  J R Soc Med       Date:  1995-07       Impact factor: 5.344

Review 4.  Early and late outcome of cystic fibrosis screening.

Authors:  M R Green; L T Weaver
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

5.  Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.

Authors:  R G Gregg; B S Wilfond; P M Farrell; A Laxova; D Hassemer; E H Mischler
Journal:  Am J Hum Genet       Date:  1993-03       Impact factor: 11.025

6.  Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.

Authors:  L T Weaver; M R Green; K Nicholson; J Mills; M E Heeley; J A Kuzemko; S Austin; G A Gregory; A E Dux; J A Davis
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

7.  Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening.

Authors:  S Chatfield; G Owen; H C Ryley; J Williams; M Alfaham; M C Goodchild; P Weller
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

8.  Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.

Authors:  M R Green; L T Weaver; A F Heeley; K Nicholson; J A Kuzemko; D E Barton; R McMahon; S J Payne; S Austin; J R Yates
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.